从药品参比制剂审议未通过和调出品种视角思考参比制剂的遴选
Chinese Pharmaceutical Affairs（2022）
Abstract
随着参比制剂审议未通过和调出参比目录数量逐渐增多,笔者首次对该类品种进行梳理,并首次针对"典型问题"通过案例深入分析其无法获得参比制剂地位的关键因素,进一步厘清参比制剂的遴选思路,并提出切实可行的遴选建议,为今后参比制剂的遴选提供借鉴.
MoreAI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined